—
Neuroendocrine Tumors - Companies Involved in Therapeutics Development are AbbVie Inc, Advanced Accelerator Applications SA, Aegis Therapeutics LLC, Amgen Inc, Amryt Pharma plc, AVEO Pharmaceuticals Inc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corp, Chiasma Inc, Crinetics Pharmaceuticals Inc, Daiichi Sankyo Company Ltd, DexTech Medical AB, Eisai Co Ltd, Eli Lilly and Company, Esperance Pharmaceuticals Inc, Exelixis Inc, Foresee Pharmaceuticals LLC, Hutchison MediPharma Ltd, INVENT Pharmaceuticals Inc, Ipsen SA, Jiangsu Hengrui Medicine Co Ltd, Karyopharm Therapeutics Inc, Lexicon Pharmaceuticals Inc, Mateon Therapeutics Inc, Merck & Co Inc, Midatech Pharma Plc, Millennium Pharmaceuticals Inc, MolMed SpA, Northwest Biotherapeutics Inc, Novartis AG, Peptron Inc, Pfizer Inc, Pharma Mar SA, Progenics Pharmaceuticals Inc, Provectus Biopharmaceuticals Inc, Strongbridge Biopharma plc, Taiwan Liposome Company Ltd, Threshold Pharmaceuticals Inc, Vascular Biogenics Ltd and Xencor Inc.Neuroendocrine tumor begins in the hormone-producing cells of the bodys neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety and gastric ulcer disease. Treatments include surgery, radiation therapy and chemotherapy.
Order a copy at http://www.reportsnreports.com/purchase.aspx?name=786902
The Neuroendocrine Tumors (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 26, 18 and 12 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 1 molecules, respectively.
Neuroendocrine Tumors (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Inquire more about this report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=786902
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
• The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors (Oncology).
• The pipeline guide reviews pipeline therapeutics for Neuroendocrine Tumors (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Neuroendocrine Tumors (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Neuroendocrine Tumors (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors (Oncology)
Reasons to buy
• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Neuroendocrine Tumors (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Neuroendocrine Tumors (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Contact Info:
Name: Ritesh Tiwari
Email: Send Email
Organization: ReportsnReports
Website: http://www.reportsnreports.com/reports/786902-neuroendocrine-tumors-pipeline-review-h2-2016.html
Release ID: 155171
Google
RSS